查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1618279

重症肌无力治疗的全球市场的评估:各类药物，各终端用户，各地区，机会，预测(2018年～2032年)

Myasthenia Gravis Treatment Market Assessment, By Drug Class, By End-user, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 233 Pages | 商品交期: 3-5个工作天内

价格

全球重症肌无力治疗市场规模预计将从 2024 年的 19.4 亿美元增至 2032 年的 33.7 亿美元，预计 2025-2032 年复合年增长率为 7.15%。由于重症肌无力的盛行率不断增加、用于治疗的免疫疗法的技术进步以及投资者对重症肌无力治疗市场的兴趣不断增长，预计重症肌无力治疗的市场需求将呈指数级增长。

重症肌无力是一种慢性神经肌肉接头疾病，也是一种自体免疫疾病，由阻断或破坏神经和肌肉连接处烟碱乙酰胆碱受体的抗体引起。盛行率约为每百万人100至350人，最近的人口调查显示，51%的重症肌无力患者初期症状表现为复视、上眼睑下垂等眼部症状。约 54.5% 的眼肌无力患者进展为全身性重症肌无力，其特征是广泛的肌肉无力。症状通常在诊断后 2 年内达到高峰，15% 至 20% 的患者会出现肌无力危象，可能导致呼吸衰竭。新产品和治疗方法的推出将进一步推动市场成长。例如，2023 年 9 月，Recipharm AB 与 AHEAD THERAPEUTICS SL 合作开发了一种治疗重症肌无力的新疗法。 Recipharm AB 为封装抗原胜肽的脂质奈米颗粒提供分析、製程开发和 GLP 製造服务。该合作伙伴关係旨在解决影响全球约 15 万人的市场中未满足的需求，并扩大生产规模以实现治疗商业化。

本报告提供全球重症肌无力治疗市场相关调查分析，市场规模与预测，市场动态，提供着主要企业的形势等。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 全球重症肌无力治疗市场预测(2018年～2032年)

  • 市场规模的分析与预测
    • 金额
  • 市场占有率的分析与预测
    • 各类药物
    • 各终端用户
    • 各地区
    • 市场占有率分析:各企业(金额)(前五名公司和其他 - 2024年)
  • 市场地图分析(2024年)
    • 各类药物
    • 各终端用户
    • 各地区

第5章 北美的重症肌无力治疗市场预测(2018年～2032年)

  • 市场规模的分析与预测
    • 金额
  • 市场占有率的分析与预测
    • 各类药物
    • 各终端用户
    • 占有率:各国
  • 各国的市场评估
    • 美国的重症肌无力治疗市场预测(2018年～2032年)
    • 加拿大
    • 墨西哥

第6章 欧洲的重症肌无力治疗市场预测(2018年～2032年)

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 波兰

第7章 亚太地区的重症肌无力治疗市场预测(2018年～2032年)

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第8章 南美的重症肌无力治疗市场预测(2018年～2032年)

  • 巴西
  • 阿根廷

第9章 中东·非洲的重症肌无力治疗市场预测(2018年～2032年)

  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非
  • 以色列

第10章 供需分析

第11章 价值链分析

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

  • 推动市场要素
  • 市场课题

第16章 市场趋势与发展

第17章 法规结构和革新

  • 法规当局的认证
  • 临床试验

第18章 专利形势

第19章 案例研究

第20章 竞争情形

  • 前五名市场领导者的竞争矩阵
  • 前五名公司的SWOT分析
  • 前十大主要企业的形势
    • Astellas Pharma Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Veloxis Pharmaceuticals, Inc.
    • Grifols, S.A.
    • Alexion Pharmaceuticals, Inc.
    • AbbVie Inc.
    • Pfizer Inc.
    • Bausch Health Companies Inc.
    • GlaxoSmithKline plc.

第21章 策略性推荐

第22章 本公司相关资料，免责声明

Product Code: MX12429

Global myasthenia gravis treatment market is projected to witness a CAGR of 7.15% during the forecast period 2025-2032, growing from USD 1.94 billion in 2024 to USD 3.37 billion in 2032. The market demand for myasthenia gravis treatment is anticipated to thrive drastically in the forecast years due to the increasing prevalence of myasthenia gravis and technological advancements in immunotherapy for their treatment, as well as the growing interest of investors in the myasthenia gravis treatment market.

Myasthenia gravis is a chronic neuromuscular junction disease, an autoimmune disorder caused by antibodies blocking or destroying nicotinic acetylcholine receptors at the nerve and muscle junction. With a prevalence of around 100-350 cases per million people, a recent population study revealed that 51% of myasthenia gravis cases present initial symptoms as ocular issues, such as double vision or drooping eyelids. Approximately 54.5% of individuals with ocular MG progress to generalized myasthenia gravis, characterized by widespread muscle weakness. Symptoms typically peak in severity within two years of diagnosis, with 15%-20% of patients experiencing myasthenia crises, posing a risk of respiratory failure. The launch of new products and therapies further fuels market growth. For instance, in September 2023, Recipharm AB partnered with AHEAD THERAPEUTICS S.L. to develop a novel therapy for myasthenia gravis. Recipharm AB will provide analytical, process development, and GLP manufacturing services for lipid nanoparticles encapsulating an antigen peptide. This collaboration aims to scale up production for commercializing therapy, addressing the unmet need in a market affecting around 150,000 people globally.

Increasing Prevalence of Myasthenia Gravis

Incidences of myasthenia gravis are increasing worldwide, and this is contributing to the growth of the myasthenia gravis treatment market. Some contributing factors to this incidence include genetic predisposition and rising awareness levels, thereby increasing demand for proper treatment solutions. High diagnosis rates of myasthenia gravis are obtained because of improved diagnosis capabilities and a better understanding of the abilities involved. As the diagnosis rate rises and the patient population seeks better treatments, the subsequent demand for treatment rises, shortly depicting significant growth of the myasthenia gravis treatment market. For instance, in June 2023, argenx SE announced that the United States FDA had approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), a subcutaneous injection for treating generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive, representing approximately 85% of the patient population.

Advancements in Diagnostic Techniques

Diagnostic technology advancements are a major growth driver of the global myasthenia gravis treatment market. Advanced diagnostic technologies, including next-generation antibody tests, neuroimaging, and electromyography, have increased the sensitivity of early detection and improved diagnostic accuracy, thus making clinicians raise myasthenia gravis quickly and at higher accuracy. Thus, with earlier interventions, patients' chances of management and relief from quality of life have increased considerably. These advances also require treatment since more cases will be diagnosed at an earlier phase, encouraging pharmaceutical and biotechnology companies to invest in innovative therapies addressing the initial and progressive stages of myasthenia gravis. For instance, in April 2023, CSL Limited announced FDA approval of a 50mL/10g prefilled syringe for Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid), the first and only immune globulin available in prefilled syringes. Hizentra offers a convenient, ready-to-use option for patients with primary immunodeficiency or chronic inflammatory demyelinating polyneuropathy.

Monoclonal Antibodies Segment to Dominate Myasthenia Gravis Treatment Market

The market for myasthenia gravis treatment is likely to be dominated by the monoclonal antibody segment because monoclonal antibodies are relatively effective for targeted therapy to manage an autoimmune response. This blockage of specific immune pathways, such as the complement system and acetylcholine receptor-related pathways, reduces symptom severity and disease progression among myasthenia gravis patients. This segment is expected to grow rapidly in the myasthenia gravis treatment market owing to its high efficacy, adoption, and pricing. For instance, in August 2023, AstraZeneca plc announced that Japan's Ministry of Health, Labour and Welfare (MHLW) had approved Soliris (eculizumab) for the extended treatment of generalized myasthenia gravis in pediatric patients who are anti-acetylcholine receptor (AChR) antibody-positive and have difficulty controlling symptoms with other treatments. Soliris is the first drug approved in Japan for children and adolescents with generalized myasthenia gravis.

North America Dominates Myasthenia Gravis Treatment Market

North America is likely to dominate the global myasthenia gravis treatment market due to high-class healthcare infrastructure and a strong pharmaceutical landscape. According to a report published in Muscle & Nerve journal, in December 2023, the diagnosed prevalence and incidence of myasthenia gravis in the United States were 37.0 and 3.1 per 100,000 persons, respectively. Higher rates were observed in younger women under the age of 50 years and older men above the age of 65 years, highlighting age- and gender-related trends in myasthenia gravis prevalence and incidence. Contributing factors for the largest share held by North America in its regional market are the increase in awareness of myasthenia gravis and growth in the myasthenia gravis treatment options. For instance, in October 2023, UCB S.A., a global biopharmaceutical company, announced that the United States Food and Drug Administration had approved ZILBRYSQ (zilucoplan) for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. ZILBRYSQ is the first once-daily, subcutaneous C5 inhibitor offering a self-administered, targeted therapy for generalized myasthenia gravis patients.

Future Market Scenario (2025-2032F)

The market for myasthenia gravis treatment is promising growth in the forecast period, mainly due to the continued advancement in the development of biological therapies, especially monoclonal antibodies, as well as an increasing pipeline of targeted therapies. Improved diagnostic competencies will lead to proper and timely diagnosis and intervention, fueling demand for more effective treatments. The rising incidence of autoimmune disorders, particularly among the geriatric population, will also contribute positively to the market growth. For instance, in June 2024, Johnson & Johnson Services, Inc. announced positive results from the Phase 3 Vivacity-MG3 study, showing that nipocalimab, combined with standard of care (SOC), outperformed placebo plus SOC in improving the MG-ADL (Myasthenia Gravis - Activities of Daily Living) score in generalized myasthenia gravis patients over 24 weeks. These findings will be presented at the EAN 2024 Congress and submitted to regulatory authorities later this year.

Key Players Landscape and Outlook

Myasthenia gravis treatment market is mainly dominated by larger pharmaceutical market players. Market activity reported in recent years includes business agreements, collaborations, clinical advancements, and regulatory approvals for market players' products. The market also fosters several smaller players, collaborating with other players to cater to a larger market. For instance, in November 2023, Selecta Biosciences, Inc., merged with Cartesian Therapeutics, Inc., a clinical-stage biotech focused on RNA cell therapies for autoimmune diseases. Following the merger, Selecta secured USD 60.25 million in private financing, bringing total funds to over USD 110 million. The combined company will advance Cartesian's pipeline, including the Phase 3 study of Descartes-08, a potential first-in-class RNA-engineered CAR-T therapy for myasthenia gravis.

In October 2024, Amgen Inc. announced positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA (inebilizumab-cdon) for treating adults with generalized myasthenia gravis. The trial met its primary endpoint, with a statistically significant change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score for UPLIZNA compared with placebo at Week 26 for the combined study population.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Myasthenia Gravis Treatment Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Drug Class
      • 4.2.1.1. Cholinesterase Inhibitors
      • 4.2.1.2. Corticosteroids
      • 4.2.1.3. Monoclonal Antibodies
      • 4.2.1.4. Rapid Immunotherapies
      • 4.2.1.5. Others
    • 4.2.2. By End-user
      • 4.2.2.1. Hospital Pharmacies
      • 4.2.2.2. Retail Pharmacies
      • 4.2.2.3. Online Pharmacies
    • 4.2.3. By Region
      • 4.2.3.1. North America
      • 4.2.3.2. Europe
      • 4.2.3.3. Asia-Pacific
      • 4.2.3.4. South America
      • 4.2.3.5. Middle East and Africa
    • 4.2.4. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Drug Class
    • 4.3.2. By End-user
    • 4.3.3. By Region

5. North America Myasthenia Gravis Treatment Market Outlook, 2018-2032F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. Cholinesterase Inhibitors
      • 5.2.1.2. Corticosteroids
      • 5.2.1.3. Monoclonal Antibodies
      • 5.2.1.4. Rapid Immunotherapies
      • 5.2.1.5. Others
    • 5.2.2. By End-user
      • 5.2.2.1. Hospital Pharmacies
      • 5.2.2.2. Retail Pharmacies
      • 5.2.2.3. Online Pharmacies
    • 5.2.3. By Country Share
      • 5.2.3.1. United States
      • 5.2.3.2. Canada
      • 5.2.3.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Myasthenia Gravis Treatment Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Drug Class
          • 5.3.1.2.1.1. Cholinesterase Inhibitors
          • 5.3.1.2.1.2. Corticosteroids
          • 5.3.1.2.1.3. Monoclonal Antibodies
          • 5.3.1.2.1.4. Rapid Immunotherapies
          • 5.3.1.2.1.5. Others
        • 5.3.1.2.2. By End-user
          • 5.3.1.2.2.1. Hospital Pharmacies
          • 5.3.1.2.2.2. Retail Pharmacies
          • 5.3.1.2.2.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Myasthenia Gravis Treatment Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Myasthenia Gravis Treatment Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Myasthenia Gravis Treatment Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Myasthenia Gravis Treatment Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Regulatory Approvals
  • 17.2. Clinical Trials

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Astellas Pharma Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
    • 20.3.2. Novartis AG
    • 20.3.3. F. Hoffmann-La Roche Ltd
    • 20.3.4. Veloxis Pharmaceuticals, Inc.
    • 20.3.5. Grifols, S.A.
    • 20.3.6. Alexion Pharmaceuticals, Inc.,
    • 20.3.7. AbbVie Inc.
    • 20.3.8. Pfizer Inc.
    • 20.3.9. Bausch Health Companies Inc.
    • 20.3.10. GlaxoSmithKline plc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 3. Global Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 4. Global Myasthenia Gravis Treatment Market Share (%), By Region, 2018-2032F
  • Figure 5. North America Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 6. North America Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 7. North America Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 8. North America Myasthenia Gravis Treatment Market Share (%), By Country, 2018-2032F
  • Figure 9. United States Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 10. United States Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 11. United States Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 12. Canada Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 13. Canada Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 14. Canada Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 15. Mexico Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Mexico Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 17. Mexico Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 18. Europe Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 19. Europe Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 20. Europe Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 21. Europe Myasthenia Gravis Treatment Market Share (%), By Country, 2018-2032F
  • Figure 22. Germany Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 23. Germany Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 24. Germany Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 25. France Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 26. France Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 27. France Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 28. Italy Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Italy Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 30. Italy Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 31. United Kingdom Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 32. United Kingdom Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 33. United Kingdom Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 34. Russia Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 35. Russia Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 36. Russia Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 37. Netherlands Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 38. Netherlands Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 39. Netherlands Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 40. Spain Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. Spain Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 42. Spain Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 43. Turkey Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 44. Turkey Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 45. Turkey Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 46. Poland Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 47. Poland Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 48. Poland Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 49. South America Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 50. South America Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 51. South America Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 52. South America Myasthenia Gravis Treatment Market Share (%), By Country, 2018-2032F
  • Figure 53. Brazil Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 54. Brazil Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 55. Brazil Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 56. Argentina Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Argentina Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 58. Argentina Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 59. Asia-Pacific Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 60. Asia-Pacific Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 61. Asia-Pacific Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 62. Asia-Pacific Myasthenia Gravis Treatment Market Share (%), By Country, 2018-2032F
  • Figure 63. India Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 64. India Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 65. India Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 66. China Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 67. China Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 68. China Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 69. Japan Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. Japan Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 71. Japan Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 72. Australia Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 73. Australia Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 74. Australia Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 75. Vietnam Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 76. Vietnam Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 77. Vietnam Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 78. South Korea Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 79. South Korea Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 80. South Korea Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 81. Indonesia Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 82. Indonesia Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 83. Indonesia Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 84. Philippines Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 85. Philippines Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 86. Philippines Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 87. Middle East & Africa Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 88. Middle East & Africa Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 89. Middle East & Africa Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 90. Middle East & Africa Myasthenia Gravis Treatment Market Share (%), By Country, 2018-2032F
  • Figure 91. Saudi Arabia Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 92. Saudi Arabia Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 93. Saudi Arabia Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 94. UAE Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 95. UAE Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 96. UAE Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 97. South Africa Myasthenia Gravis Treatment Market, By Value, In USD Billion, 2018-2032F
  • Figure 98. South Africa Myasthenia Gravis Treatment Market Share (%), By Drug Class, 2018-2032F
  • Figure 99. South Africa Myasthenia Gravis Treatment Market Share (%), By End-user, 2018-2032F
  • Figure 100. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 101. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 102. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024